{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:40:20Z","timestamp":1787726420125,"version":"build-2784847793"},"reference-count":30,"publisher":"The Endocrine Society","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,3,1]]},"DOI":"10.1210\/js.2017-00432","type":"journal-article","created":{"date-parts":[[2018,2,6]],"date-time":"2018-02-06T14:06:32Z","timestamp":1517925992000},"page":"241-251","source":"Crossref","is-referenced-by-count":180,"title":["Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study"],"prefix":"10.1210","volume":"2","author":[{"given":"Tomoko","family":"Kobayashi","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shintaro","family":"Iwama","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan"},{"name":"Research Center of Health, Physical Fitness and Sports, Nagoya University, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Yasuda","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Okada","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taku","family":"Tsunekawa","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Onoue","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Takagi","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Hagiwara","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Morishita","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motomitsu","family":"Goto","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetaka","family":"Suga","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoichi","family":"Banno","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Yokota","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsunari","family":"Hase","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Morise","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naozumi","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Ando","sequence":"additional","affiliation":[{"name":"Center for Advanced Medicine and Clinical Research, Nagoya University Hospital, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Kiyoi","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Momokazu","family":"Gotoh","sequence":"additional","affiliation":[{"name":"Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Ando","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Akiyama","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Arima","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2018,2,6]]},"reference":[{"issue":"19","key":"key\n\t\t\t\t20180301121057_B1","doi-asserted-by":"crossref","first-page":"12293","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","author":"Iwai","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"issue":"18","key":"key\n\t\t\t\t20180301121057_B2","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMra1514296","article-title":"Molecular and biochemical aspects of the PD-1 checkpoint pathway","volume":"375","author":"Boussiotis","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"key\n\t\t\t\t20180301121057_B3","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"17","key":"key\n\t\t\t\t20180301121057_B4","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"issue":"19","key":"key\n\t\t\t\t20180301121057_B5","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"issue":"19","key":"key\n\t\t\t\t20180301121057_B6","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"key\n\t\t\t\t20180301121057_B7","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"issue":"10111","key":"key\n\t\t\t\t20180301121057_B8","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","article-title":"Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Kang","year":"2017","journal-title":"Lancet"},{"issue":"12","key":"key\n\t\t\t\t20180301121057_B9","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1007\/s40265-015-0442-6","article-title":"Nivolumab: a review in advanced melanoma","volume":"75","author":"Scott","year":"2015","journal-title":"Drugs"},{"issue":"1","key":"key\n\t\t\t\t20180301121057_B10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"key\n\t\t\t\t20180301121057_B11","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1634\/theoncologist.2015-0509","article-title":"Immune checkpoint inhibitors: review and management of endocrine adverse events","volume":"21","author":"Gonz\u00e1lez-Rodr\u00edguez","year":"2016","journal-title":"Oncologist"},{"key":"key\n\t\t\t\t20180301121057_B12","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J. Clin Oncol"},{"key":"key\n\t\t\t\t20180301121057_B13","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.2337\/dc14-2349","article-title":"recipitation of autoimmune diabetes with anti-PD-1 immunotherapy","volume":"38","author":"Hughes","year":"2015","journal-title":"Diabetes Care"},{"issue":"1-3","key":"key\n\t\t\t\t20180301121057_B14","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s12026-012-8302-x","article-title":"Genetic and epigenetic mechanisms in thyroid autoimmunity","volume":"54","author":"Hasham","year":"2012","journal-title":"Immunol Res"},{"issue":"8","key":"key\n\t\t\t\t20180301121057_B15","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","article-title":"Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination","volume":"13","author":"Boutros","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"key\n\t\t\t\t20180301121057_B16","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2217\/imt-2016-0147","article-title":"Risk of endocrine adverse events in cancer patients treated with PD-1 inhibitors: a systematic review and meta-analysis","volume":"9","author":"Shang","year":"2017","journal-title":"Immunotherapy"},{"issue":"4","key":"key\n\t\t\t\t20180301121057_B17","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/cen.13297","article-title":"Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma","volume":"86","author":"Morganstein","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"key\n\t\t\t\t20180301121057_B18","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/annonc\/mdw640","article-title":"Antibody-mediated thyroid dysfunction during t-cell checkpoint blockade in patients with non-small cell lung cancer","volume":"28","author":"Osorio","year":"2017","journal-title":"Ann Oncol"},{"issue":"11","key":"key\n\t\t\t\t20180301121057_B19","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1210\/jc.2016-2300","article-title":"Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab","volume":"101","author":"de Filette","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t20180301121057_B20","doi-asserted-by":"crossref","first-page":"pii: bcr2015213692","DOI":"10.1136\/bcr-2015-213692","article-title":"Nivolumab causing painless thyroiditis in a patient with adenocarcinoma of the lung","volume":"2016","author":"Verma","year":"2016","journal-title":"BMJ Case Rep"},{"issue":"6","key":"key\n\t\t\t\t20180301121057_B21","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/jjco\/hyw036","article-title":"Nivolumab-induced thyroid dysfunction","volume":"46","author":"Tanaka","year":"2016","journal-title":"Jpn J Clin Oncol"},{"key":"key\n\t\t\t\t20180301121057_B22","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1089\/thy.2016.0562","article-title":"Clinical features of nivolumab-induced thyroiditis: a case series study","volume":"27","author":"Yamauchi","year":"2017","journal-title":"Thyroid"},{"issue":"7","key":"key\n\t\t\t\t20180301121057_B23","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy","volume":"35","author":"Naidoo","year":"2017","journal-title":"J Clin Oncol"},{"issue":"5","key":"key\n\t\t\t\t20180301121057_B24","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1097\/CMR.0000000000000384","article-title":"Fulminant type 1 diabetes after adjuvant ipilimumab therapy in cutaneous melanoma","volume":"27","author":"Tsiogka","year":"2017","journal-title":"Melanoma Res"},{"issue":"4","key":"key\n\t\t\t\t20180301121057_B25","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1210\/jc.2011-2178","article-title":"Evidence of a combined cytotoxic thyroglobulin and thyroperoxidase epitope-specific cellular immunity in Hashimoto\u2019s thyroiditis","volume":"97","author":"Ehlers","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"key\n\t\t\t\t20180301121057_B26","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1089\/thy.2015.0170","article-title":"Thyroid dysfunction in patients with metastatic carcinoma treated with sunitinib: is thyroid autoimmunity involved","volume":"25","author":"Pani","year":"2015","journal-title":"Thyroid"},{"key":"key\n\t\t\t\t20180301121057_B27","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ctrv.2017.06.002","article-title":"Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management","volume":"58","author":"Sznol","year":"2017","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"key\n\t\t\t\t20180301121057_B28","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/1346-8138.13437","article-title":"Case of hypophysitis caused by nivolumab","volume":"44","author":"Ishikawa","year":"2017","journal-title":"J Dermatol"},{"key":"key\n\t\t\t\t20180301121057_B29","first-page":"16","article-title":"Hyponatraemia secondary to nivolumab-induced primary adrenal failure","volume":"2016","author":"Trainer","year":"2016","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"4","key":"key\n\t\t\t\t20180301121057_B30","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","article-title":"Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes","volume":"22","author":"Freeman-Keller","year":"2016","journal-title":"Clin Cancer Res"}],"container-title":["Journal of the Endocrine Society"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jes\/article-pdf\/2\/3\/241\/24226823\/js.2017-00432.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T20:02:20Z","timestamp":1660420940000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jes\/article\/2\/3\/241\/4840685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,6]]},"references-count":30,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,2,6]]},"published-print":{"date-parts":[[2018,3,1]]}},"URL":"https:\/\/doi.org\/10.1210\/js.2017-00432","relation":{},"ISSN":["2472-1972"],"issn-type":[{"value":"2472-1972","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,3]]},"published":{"date-parts":[[2018,2,6]]}}}